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Abstract
The most common cause of dilated cardiomyopathy and heart failure (HF) is ischemic heart 
disease; however, in a third of all patients the cause remains undefined and patients are diagnosed 
as having idiopathic dilated cardiomyopathy (IDC). Recent studies suggest that many patients with 
IDC have a family history of HF and rare genetic variants in over 35 genes have been shown to be 
causative of disease. We employed whole-exome sequencing to identify the causative variant in a 
large family with autosomal dominant transmission of dilated cardiomyopathy. Sequencing and 
subsequent informatics revealed a novel 10-nucleotide deletion in the BCL2-associated 
athanogene 3 (BAG3) gene ((Ch10:del 121436332_12143641: del. 1266_1275 [NM 004281]) that 
segregated with all affected individuals. The deletion predicted a shift in the reading frame with 
the resultant deletion of 135 amino acids from the C-terminal end of the protein. Consistent with 
genetic variants in genes encoding other sarcomeric proteins there was a considerable amount of 
genetic heterogeneity in the affected family members. Interestingly, we also found that the levels 
of BAG3 protein were significantly reduced in the hearts from unrelated patients with end-stage 
HF undergoing cardiac transplantation when compared with non-failing controls. Diminished 
levels of BAG3 protein may be associated with both familial and non-familial forms of dilated 
cardiomyopathy.
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Heart failure (HF) secondary to systolic dysfunction and cardiac dilatation affects over 5 
million individuals in the U.S. and is an important cause of both morbidity and mortality. 
Approximately 30% of these patients have non-ischemic disease or idiopathic dilated 
cardiomyopathy (IDC). Although in the majority of patients with IDC the causative factors 
have remained undefined, emerging evidence suggests that up to 35% of individuals with 
IDC have an affected first degree relative1 and IDC can be associated with genetic 
abnormalities in 20-35% of individuals – leading to the use of the nomenclature familial 
dilated cardiomyopathy (FDC).2, 3Indeed, mutations in more than 30 genes have been 
identified as causative factors.4 and the most common pattern of inheritance is autosomal 
dominant with reduced penetrance and variable expressivity.5
Mutations causing FDC are found in genes encoding a wide spectrum of proteins6; however, 
a large number of the mutations that cause FDC occur in genes that encode sarcomere 
proteins or the complex network of proteins in the Z-disc6, 7 Recently, mutations in Bcl-2 
associated anthanogene-3 (BAG3), a 575 amino acid anti-apoptotic protein that serves as a 
co-chaperone of the heat shock proteins (HSPs), have also been associated with FDC. 8-10 
For example, Norton et al. recently identified a deletion of BAG3 exon 4 as a rare variant 
causative of FDC in a family without neuropathy or peripheral muscle weakness.11 
Subsequent sequencing of BAG3 in subjects diagnosed with IDC identified four additional 
mutations that segregated with all relatives affected by the disease. A genome-wide 
association study conducted in patients with HF secondary to IDC implicated a non-
synonymous single nucleotide polymorphism (SNP) (c.757T>C, [p. Cys151Arg]) located 
within the BAG3 gene as contributing to sporadic dilated cardiomyopathy.12
In the present study, we identified a novel BAG3 mutation in a family with adult-onset FDC. 
Furthermore, we report for the first time that BAG3 protein levels are significantly 
decreased in unrelated patients with non-familial IDC suggesting that altered levels of 
BAG3 protein may participate in the progression of HF.
METHODS
We identified a family with adult-onset familial dilated cardiomyopathy. After obtaining 
informed consent, participating family members underwent a physical examination by a 
heart failure cardiologist and blood was collected for subsequent DNA analysis. DNA was 
extracted using a DNA extraction kit (Qiagen, Valencia CA) and stored at −70°C. Whenever 
possible, electrocardiograms were obtained from affected family members who had not 
undergone heart transplantation. Family members who had not had a recent echocardiogram 
underwent a transthoracic echocardiogram using a SonoHeart Elite (SonoSite Inc, Bothell, 
Washington, USA) portable echocardiographic system. Medical records were obtained from 
one individual who had died. Affection status was determined on the basis of consensus 
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guidelines.13 Participating family members provided written informed consent prior to 
evaluation and the protocols were approved by the Internal Review Boards of Thomas 
Jefferson University and of the University of Colorado.
Human heart tissue was obtained from 9 subjects unrelated to our study family with end-
stage heart failure undergoing heart transplant at Temple University Hospital (6 male, 3 
female, mean age 47.6 + 5.7 years), from one affected family member at the time of heart 
transplantation at the University of Colorado and from 7 organ donors (1 male, 6 female, 
mean age 59.3 ± 3.7 years) whose hearts were unsuitable for donation owing to blood type, 
age or size incompatibility. All of the patients undergoing transplantation had severe left 
ventricular dysfunction and cardiac dilation with a mean left ventricular ejection fraction 
(LVEF) of 12.8 + 1.4%. Two of the transplant recipients had HF secondary to ischemic 
cardiomyopathy and the remainder had non-ischemic IDC. Four of the transplant recipients 
were receiving dobutamine alone, 5 were receiving milrinone alone and one was receiving 
both milrinone and dobutamine at the time of the transplantation. Echocardiography was 
performed on all of the organ donors prior to organ donation and all had normal left 
ventricular function by echocardiography with a mean LVEF of 57.5 + 1.6%. Tissue 
aliquots were removed from the left ventricular free wall, rapidly frozen in liquid nitrogen 
and stored at −70°C as described previously.14 The Institutional Review Boards of the 
University of Colorado and Temple University approved the tissue study and consent was 
obtained for all subjects.
Exome Sequencing and Bioinformatics
DNA from 5 affected family members and 1 unaffected family member was selected for 
exome sequencing with a target depth of >100X. Exome enrichment was performed using 
the Agilent SureSelect Human Exon 51Mb kit (Agilent, Santa Clara, CA). Paired-end 100 
nucleotide exome sequencing was performed using an Illumina HiSeq 2000 platform (San 
Diego, CA). Sequence reads passing Illumina chastity filter, were subjected to a quality 
filter step, trimmed and retained if the trimmed reads for each pair exceeded 50 nucleotides. 
Paired reads were then mapped to the reference human genome sequence (hg19) with 
gSNAP15 Sequence calls for variants (single-nucleotide polymorphisms [SNPs)] insertions 
and deletions [indels]) were performed using the Broad’s Genome Analysis Toolkit16
After variant detection, the program Annotate Variation (ANNOVAR) was used to classify 
variants (e.g., exonic, intronic, synonymous, non-synonymous, splice variant, stop gain, stop 
loss, insertion, or deletion) and to cross reference all the variants across various genetic 
variation databases (e.g., dbSNP, 1000 genomes database, AVSIFT) to isolate rare variants 
(variants with mean allele frequencies of <1% not found in dbSNP, 1000 genomes database, 
aVSIFT).17 Only non-synonymous changes (SNPs and in-dels), those that cause an alternate 
splice site, and/or an aberrant stop codon, were considered for further analysis. For non-
synonymous changes, all insertion and deletion variants were considered damaging, whereas 
SNP variants were cross-referenced to the dbNSFP database to determine whether the 
changes to the protein structure would be considered tolerable or damaging using four 
algorithms (Sorting Intolerant From Tolerant (SIFT), PolyPhen2, likelihood ratio test [LRT], 
or MutationTaster).18 Putative mutations identified were confirmed with traditional Sanger 
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sequencing in both affected and unaffected family members (primers and conditions 
available upon request).
Western Blot Analysis of Human Heart Tissue
Frozen tissue was homogenized in 40 mM Tris buffer, pH 7.5 containing 150 mM NaCl, 1% 
NP40, 1 mM DTT, and 1 mM EDTA. The sample was then centrifuged at 10,000 × g at 4°C 
for 30 min and the supernatant was collected and re-suspended in 350 DM Tris buffer, pH 
6.8 containing 25% beta-mercaptoethanol, 30% glycerol, 10% SDS, and 2% bromophenol 
blue. The protein concentration was measured using the method of Bradford and the samples 
were stored at −80°C. Equal amounts of protein (10ug) were fractionated by SDS-
polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane. 
Membranes were blocked in 10% nonfat dry milk/tris-buffered saline (pH 7.6) plus 0.1% 
Tween-20 (TBS-T) for 1 h and then incubated with polyclonal BAG3 antibody (Proteintech, 
Chicago, IL) in 5% nonfat dry milk with PBST for 2 hrs. Membranes were then incubated 
with goat-anti-rabbit 800 and goat-anti-mouse secondary antibody for 1 hr and scanned on a 
LI-COR Odyssey imaging system (Lincoln NE). All Western blot procedures were carried 
out at room temperature. BAG3 signal intensity was normalized to GAPDH.
RESULTS
Family history
The proband (Figure 1, III-5) was a 65 year-old woman of Eastern European ancestry who 
was referred in June 2003 to the heart failure clinic at Thomas Jefferson University because 
of a family history of HF. She had first been noted to have a dilated cardiomyopathy at 45 
years of age. She was largely asymptomatic while receiving a diuretic, a β-adrenergic 
receptor antagonist (β-blocker) and an angiotensin converting enzyme (ACE) inhibitor Her 
vital signs were within normal limits and her physical examination was notable only for a 
soft S3 heart sound. She had no peripheral muscle weakness and her neurologic examination 
was unremarkable. Her electrocardiogram revealed normal sinus rhythm with mild LV 
hypertrophy and non-specific ST-T wave changes. Her left ventricular ejection fraction was 
20% by echocardiography. As seen in Figure 1 and Table 1, the proband had two female 
siblings, one of whom (III-7) was asymptomatic with a normal physical examination; 
however, her ejection fraction by echocardiography was 44%. A second sister (III-9) was 
phenotypically normal and had a normal echocardiogram.
The proband had three children. A son underwent cardiac transplantation at the age of 20 
secondary to IDC ( IV-5 ), A second son was diagnosed with idiopathic dilated 
cardiomyopathy at the age of 20 but remained asymptomatic at age 32 despite an ejection 
fraction of 33% (IV-4). A daughter had no cardiac symptoms; however, her left ventricular 
ejection fraction by echocardiography was 48% and she had mild dilatation of the left 
ventricle and the aortic root without obvious aortic valve disease. (IV-6) Her 
echocardiogram met the criteria for diagnosis of a dilated cardiomyopathy. Her 
electrocardiogram was normal. Neurologic function was normal in all three children. The 
proband’s affected sister (III-7) had one daughter who died of progressive heart failure 
secondary to IDC at the age of 22 (IV-7): two other children had normal echocardiograms. 
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A cousin underwent cardiac transplantation because of IDC at 42 years of age after 
diagnosis at the age of 40 (III-1) and one of his sons also underwent cardiac transplantation 
for IDC at the University of Colorado at the age of 30 (IV-1). Healthy subjects were defined 
as “non-affected” if they had reached the age of 40 without symptoms and had a normal 
echocardiogram that did not meet the criteria for diagnosis of a cardiomyopathy. Ten-year 
follow-up of all participants demonstrated that functional capacity had remained stable in all 
family members.
Genetic analysis
As seen in Figure 1, the pedigree and clinical data were compatible with autosomal 
dominant adult-onset familial IDC. Exome sequencing of the DNA from 5 affected (III-5, 7: 
IV-1,4,5) and 1 unaffected (III-9) family members had an average of 11.8 + 0.96 Gb of past-
filter sequence reads per sample. After bioinformatics filtering a 10-nucleotide deletion in 
the coding portion of exon 4 of BAG3 (Ch10:del 121436332_12143641: del. 1266_1275 
[NM 004281]) was noted to be present in all tested affected subjects and absent in the one 
healthy sister of the proband (III-9) (Figure 2) Additional family members were tested for 
the BAG3 deletion by Sanger sequencing confirming appropriate co-segregation of the 
deletion with the phenotype among affected (III-1,5,7 and IV-1,4,5,6) and unaffected (III-9 
and IV-8,9,10,11,12) individuals. This deletion was not found in existing databases and 
introduces a frame shift and premature stop codon after 13 amino acids that predicts 
truncation of BAG3 at the carboxy terminal end by 140 amino acids. Thus, the abnormal 
BAG3 protein is predicted to have 435 amino acids instead of 575 amino acids. In addition, 
the amino acid sequence distal to the deletion (K P S W R R Y R G W S R L) is predicted to 
be different from that found in the normal protein. Only one additional variant was found by 
exome sequencing and after bioinformatics filtering. The variant (rs8192669), found in the 
IKZF5 gene did not segregate according to the IDC phenotype in other family members. An 
analysis of 52 genes previously associated with monogenic IDC for rare variants (<1%) 
identified only non-synonymous mutations in TTN, GATAD1, MYPN, ANKRD1 and RBM20: 
none of these variants segregated with the disease phenotype.
BAG3 expression in failing human heart
In order to determine whether the BAG3 deletion (BAG3 del. NM_004281) found in this 
patient cohort resulted in a decrease in the levels of BAG3 protein, Western blot analysis 
was performed on cardiac muscle obtained from one affected family member (IV-1) who 
underwent cardiac transplantation. The level of BAG3 protein in subject IV-1 was less than 
half that seen in heart tissue obtained from organ donors whose heart could not be utilized 
for transplantation. As seen in Figure 3, BAG3 levels in failing human heart from patients 
with end stage heart failure without known BAG3 mutations were significantly (p = 0.0002) 
less than that found in non-failing control hearts. Thus it appears that decreased levels of 
BAG3 protein can be found both in individuals with a BAG3 mutation as well as in end-
stage failing human heart.
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It is being increasingly recognized that genetic mutations can account for as many as a third 
of cases of IDC. Indeed, investigators have begun to refer to these cases as familial dilated 
cardiomyopathy (FDC).1-3 Inheritance can occur in a variety of manners with the most 
common pattern of inheritance being autosomal dominant. 19,20.21,5 Mutations are most 
commonly found in genes encoding the sarcomere leading to cardiac dysfunction, 
disintegration of the myofiber structure and accumulation of degraded material in 
autophagic granules. 22,6, 23-26 Here, we report a 10 bp deletion in the gene encoding the 
sarcomeric protein BAG3 that segregates completely with affected individuals in a family 
with an autosomal dominant pattern of FDC. We also report for the first time that BAG3 
protein is substantially reduced in the hearts of unrelated patients who are undergoing heart 
transplantation when compared with normal hearts from transplant recipients.
BAG3 is a 575 amino acid anti-apoptotic protein that is constitutively expressed in the heart 
and serves as a co-chaperone of the heat shock proteins (HSPs).27,28 BAG3 binds to HSPs 
and regulates their ability to chaperone cytoskeletal proteins including desmin and also 
participate in degradation of cellular proteins through either the proteasome or autophagy 
pathways.28 BAG3 also protects cells from apoptotic death29 and inhibits myofibrillar 
degeneration in response to mechanical stress.30, 31 Knockdown of BAG3 in zebrafish11 or 
in neonatal cardiomyoctes30 or homozygous disruption of BAG3 in mice leads to cardiac 
dysfunction32 and BAG3 levels are decreased in the skeletal muscle of spontaneously 
hypertensive rats.33
The results of the present study in a large family with FDC are consistent with earlier reports 
that demonstrated an association between mutations in BAG3 and the development of 
muscle pathology. Mutations in BAG3 were first shown to cause abnormal muscle function 
in two families with childhood-onset muscular dystrophy8, 9 and the phenotype of IDC, 
diffuse myocardial fibrosis and sudden death was linked with markers in the chromosome 
10q25-26 region which includes the BAG3 locus.34 More recent studies have demonstrated a 
causative relationship between BAG3 mutations and the development of FDC without 
peripheral muscle weakness or neurologic findings.11,12,31
As seen with genetic variants in other sarcomeric genes, there was substantial genetic 
heterogeneity within this large family. For example, one of the proband’s sons had an early 
onset of severe disease requiring transplantation whereas a sibling with moderate disease 
and a middle-aged daughter with very mild disease remain asymptomatic for over a decade. 
Indeed, the cardiac dysfunction in the proband’s daughter would have gone unrecognized 
had it not been for careful phenotyping as part of this study. Identification of the causative 
mutation in this family provides an opportunity for guideline-driven genetic testing and 
counseling of family members and early identification of affected individuals.35 The finding 
that use of an angiotensin converting enzyme inhibitor improved survival in a small group of 
patients with Duchenne muscular dystrophy suggests that early therapy in families with 
mutations in sarcomere genes might be beneficial; however, additional studies will be 
required to define the best treatment strategies.36, 37
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We report for the first time that the level of BAG3 protein is significantly reduced in the 
hearts of unrelated patients with end-stage HF who are undergoing heart transplant and who 
have no family history of heart muscle disease. This finding is interesting as it suggests that 
while mutations in BAG3 can be causative of disease in FDC, changes in levels of BAG3 
protein might participate in the progression of disease in patients with non-familial forms of 
IDC. However, it remains to be seen whether the decrease in BAG3 levels in patients with 
IDC participated in the progression of the disease or is secondary to the disease process 
itself. Mechanistic studies will also be needed to understand the cellular and molecular 
effects responsible for the myopathy in individuals with the rare BAG3 deletion seen in this 
large family. Nonetheless, these results suggest that BAG3 protein might be a new target for 
therapeutic intervention in HF.
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BAG3-Associated Dilated Cardiomyopathy Pedigree. Males are represented by squares. 
Circles indicate females. Open symbols represent unaffected individuals and black symbols 
represent affected individuals. The presence or absence of the 10-nucleotide deletion in 
BAG3 is indicated by either a (+) or a (−) respectively. An arrow denotes the proband. An 
asterisk is used to denote individuals whose DNA was used for whole exome sequencing. A 
diagonal line is used to denote individuals who are deceased.
Feldman et al. Page 10














A: Sequencing alignment for BAG3 10-nucleotide deletion. B: Representative Sanger 
sequencing shows the deletion in the BAG3 gene in an affected individual.
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Representative Western blot of BAG3 and GAPDH levels in non-failing (NF) and failing (F) 
human heart. C. Quantification of BAG3 protein levels in non-failing and failing human 
heart. Values are normalized to the level of GAPDH in order to account for variations in 
protein loading. Horizontal lines represent mean and standard error of the mean. Statistical 
analysis was performed using unpaired t-test with Welch’s correction for unequal variance,
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Table 1
Phenotype of study subjects with and without a 10-nucleotide deletion in the BAG3 gene.




II-1 na/na/70+ M Died
late 70's, hx of HF
II-3 na/na/80 F Hx of
HBP and CVA
II-4 na/na/29 M motor
vehicle accident
III-1 62 /40/42 M Yes
transplant at 42
III-5 65/45/na F 20 NS-ST-T changes Yes
III-7 67/47/na F 44 nl Yes
asymptomatic
III-9 68/na/na F 58 nl No
IV-1 30/30/30 M Yes
transplant at 30
IV-4 39/20/na M 33 sinus brady, IVCD Yes
asymptomatic
IV-5 35/20/20 M Yes
transplant at 20
IV-6 34/34/na F 48 nl Yes mild
aortic root dilat, LVDD 5.8
IV-7 na/18/22 F died -
worsening HF
IV-8 38 F nl No
IV-9 42 M nl No
IV-10 41 F nl No
IV-11 44 M nl No
IV-12 45 M nl No
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